{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-009619","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.620109+00:00","generated_at":"2026-05-25T13:42:14.211097+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Esperion FY24 revenue $332.3M (+186% Y/Y); net loss narrows to $51.7M from $209.2M","bullets":["FY24 total revenue $332.3M (+186% Y/Y); Q4 revenue $69.1M (+114% Y/Y).","U.S. net product revenue FY24 $115.7M (+48% Y/Y); Q4 $31.6M (+52% Y/Y).","FY24 net loss $51.7M ($0.28/sh) vs $209.2M ($2.03/sh) in 2023; Q4 net loss $21.3M ($0.11/sh).","Announced development of two triple combination products with bempedoic acid.","Strengthened balance sheet: $304.7M from OMERS royalty deal; repaid $210M convertible debt; cash $144.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-009619","json":"https://secwatch.observer/filing/0001628280-25-009619.json","markdown":"https://secwatch.observer/filing/0001628280-25-009619.md","text":"https://secwatch.observer/filing/0001628280-25-009619.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025009619/0001628280-25-009619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025009619/espr-20250304.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T13:42:14.211097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}